

[国内版](#)[国际版](#)

Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment ar

[All](#)[Images](#)[Videos](#)[翻译成中文](#)[关闭取词](#)

409 Results

Any time ▾

[Challenges Persist With CAR T-Cell Therapy in Pancreatic ...](#)



Targeted Oncology

16 hours ago · At Penn, Beatty's laboratory developed a CAR specific for mesothelin, a protein that is overexpressed by **pancreatic ductal adenocarcinoma** cells. In vitro, CAR T cells engineered to express mesothelin "will react and kill **tumor** cells that are ...

[The Oncolytic Virotherapy Era in Cancer Management ...](#)

<https://www.frontiersin.org/articles/10.3389/fonc.2017.00093> ▾

In the respective preclinical models, efforts have been made to unravel the mechanisms and improve the efficacy of H-1PV **treatment**. **Pancreatic Cancer**. **Pancreatic ductal adenocarcinoma** (PDAC) is a highly aggressive **tumor**, often unresectable at the time ...

[Pomalidomide Alters Pancreatic Macrophage Populations to ...](#)

cancerres.aacrjournals.org/content/79/7/1535 ▾

The **microenvironment** surrounding **pancreatic** lesions and **cancer** cells is mainly composed of fibroblasts and immune cells, and is an important factor affecting **tumor** development and growth, **tumor** cell dissemination, and **treatment** efficacy.

[Inhibition of geranylgeranyl diphosphate synthase is a ...](#)

[www.nature.com](https://www.nature.com/ncancer) › [oncogene](#)

7 days ago · **Pancreatic ductal adenocarcinoma** (PDAC) is characterized by abnormal mucin production and these mucins play important roles in **tumor** ...

[TAMing pancreatic cancer: combat with a double edged ...](#)

<https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943...>

4 days ago · **Pancreatic Ductal Adenocarcinoma** (PDAC) is the most common **cancer**, constituting nearly 90% of all **pancreatic** cancers. Surgical resection continues to be the only definitive **treatment** for PDAC, yet, the fraction of patients who have **tumors** that are amenable to surgical resection is only approximately 10–20% [7].

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 47888

Manuscript Type: MINIREVIEWS

**Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor
microenvironment and immunotherapy**

Sarantis P *et al.* Immunotherapy and pancreatic cancer

Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou,
Athanasios G Papavassiliou, Michalis V Karamouzis

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases,

Match Overview

1	Internet 28 words crawled on 22-Jun-2017 www.mskcc.org	1%
2	Internet 27 words crawled on 10-Jan-2018 www.mdpi.com	1%
3	Crossref 20 words Gunturu, K. S., G. R. Rossi, and S. M. Wasif. "Immunoti ... rapy updates in pancreatic cancer: are we there yet?", Th	1%
4	Internet 20 words crawled on 10-Jan-2018 pancreapedia.org	1%
5	Internet 19 words crawled on 14-Jun-2018 science.sciencemag.org	1%
6	Internet 18 words crawled on 29-Mar-2015 www.ncbi.nlm.nih.gov	1%
7	Crossref 17 words J. M. Kim, D. S. Chen. "Immune escape to PD-L1/PD-1 ... lockade: seven steps to success (or failure)", Annals of	1%
8	Internet 15 words crawled on 18-Sep-2019 www.frontiersin.org	1%
9	Internet 15 words crawled on 08-Apr-2018 cancerbiomedcentral.com	1%
10	Crossref 13 words Elodie Roger, Sylvie Martel, Adrien Bertrand-Chapel, Arn aud Depollier et al. "Schwann cells support oncogenic ...	<1%
11	Internet 13 words crawled on 17-Jul-2018 clincancerres.aacrjournals.org	<1%



All

Images

Videos

关闭取词

27,000 Results

Any time ▾

Immunotherapy for pancreatic ductal adenocarcinoma: an ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560736>

Mar 18, 2015 · **Pancreatic ductal adenocarcinoma (PDAC)** is the fourth leading cause of **cancer-related death** and **current therapeutic strategies** are often unsatisfactory. Identification and development of more **efficacious therapies** is urgently needed.

Cited by: 14

Author: Alessandro Paniccia, Justin Merkow, Bari...

Publish Year: 2015

Pancreatic cancer microenvironment, to target or not to ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734844>

Jan 08, 2016 · The specific example of **pancreatic ductal adenocarcinoma (PDAC)** illustrates both the shortcomings of conventional **therapies** and the importance of the **PDAC microenvironment** in clinical outcomes. PDAC is a highly **lethal malignancy** with ~80% of patients presenting with locally advanced **disease**.

Cited by: 16

Author: Ryan M Carr, Martin E Fernandez-Zapico

Publish Year: 2016

Frontiers | Pancreatic Ductal Adenocarcinoma: A Strong ...

<https://www.frontiersin.org/articles/10.3389/fimmu.2018.01044> ▾

May 14, 2018 · **Pancreatic ductal adenocarcinoma (PDAC)** is one of the most aggressive and **lethal cancers** with very few available **treatments**. For many decades, **gemcitabine** was the only **treatment for patients** with PDAC.

Cited by: 11

Author: Etienne Dominique Foucher, Clément Ghi...

Publish Year: 2018

Targeting the tumor microenvironment for pancreatic ductal ...

[cco.amegroups.com/article/view/25114/23704](https://www.frontiersin.org/articles/10.3389/fimmu.2018.01044) ▾

Pancreatic ductal adenocarcinoma (PDAC) is one of the most dangerous cancers, and the overall 5-year survival rate is only 8%. The microenvironment of PDAC, which promotes tumorigenesis, disease development and **metastasis**, consists of fibroblasts, **immune cells**, **pancreatic stellate cells (PaSCs)**, adipocytes and extracellular matrix (ECM).

Author: Yi-Fan Zhang, Shu-Heng Jiang, Li-Pen...

Publish Year: 2019



All

Images

Videos

关闭取词

26,900 Results

Any time ▾

Pancreatic cancer microenvironment, to target or not to ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734844>

Jan 08, 2016 · The specific example of **pancreatic ductal adenocarcinoma (PDAC)** illustrates both the shortcomings of conventional **therapies** and the importance of the **PDAC microenvironment** in clinical outcomes. **PDAC** is a highly **lethal malignancy** with ~80% of patients presenting with locally advanced **disease**.

Cited by: 16

Author: Ryan M Carr, Martin E Fernandez-Zapico

Publish Year: 2016

Immunotherapy for pancreatic ductal adenocarcinoma: an ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560736>

Mar 18, 2015 · The **pancreatic cancer microenvironment**. **Pancreatic ductal adenocarcinoma (PDAC)** presents several challenges that set it apart from those more immunogenic **tumors**, such as melanoma and renal cell **cancer** (17,18). A dysregulation of the immune system is one of the facilitating factors for **PDAC** development, thus legitimizing the role of the immune network in **PDAC** (19-22).

Cited by: 14

Author: Alessandro Paniccia, Justin Merkow, Bari...

Publish Year: 2015

Pancreatic cancer microenvironment: a current dilemma

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333596>

Jan 15, 2019 · To date, the **mainstay treatment** of **pancreatic cancer** is a combination of **cytotoxic agents** in **adjuvant** and **metastatic settings** [5, 6]. Despite efforts in the past decades, targeted **therapy** approaches have not yielded substantial improvement in clinical outcomes essentially due to complex signaling pathways .

Cited by: 2

Author: Burak Uzunparmak, Ibrahim Halil Sahin

Publish Year: 2019

Frontiers | Pancreatic Ductal Adenocarcinoma: A Strong ...

<https://www.frontiersin.org/articles/10.3389/fimmu.2018.01044> ▾

May 14, 2018 · **Pancreatic ductal adenocarcinoma (PDAC)** is one of the most aggressive and **lethal cancers** with very few available **treatments**. For many decades, **gemcitabine** was the only **treatment** for patients with **PDAC**.

Cited by: 11

Author: Etienne Dominique Foucher, Clément Ghi...

Publish Year: 2018